Cell Therapy
CAR-T Cell Therapy
Patient T cells re-engineered ex vivo to recognize tumor antigen — the first FDA-approved gene-modified cell therapy
CAR-T therapy harvests patient T cells, transduces them with a chimeric antigen receptor against a tumor antigen (CD19 for B-cell cancers), and infuses them back. Kymriah was the first approved (2017); refractory ALL remission rates reach 60-80%.
- Dose1-5 × 10⁸ CAR+ T cells per infusion
- Manufacturing9-14 days expansion ex vivo; vein-to-vein 3-5 weeks
- First approvalKymriah · Aug 2017 · pediatric ALL
- Refractory ALL remission60-80% complete response
- Price (US list)~$400-500k per dose
- Main toxicitiesCytokine release syndrome; ICANS neurotoxicity
Interactive visualization
Press play, or step through manually. The visualization is yours to drive — try it before reading on.
Watch the 60-second explainer
A condensed visual walkthrough — narrated, captioned, under a minute.
Worked example — Emily Whitehead, the first child treated
In April 2012, 6-year-old Emily Whitehead became the first pediatric patient treated with what would become Kymriah. She had relapsed acute lymphoblastic leukemia, refractory to two rounds of chemotherapy. Her oncologists at CHOP — Carl June's group at the University of Pennsylvania — enrolled her on a phase 1 trial of CTL019, a CD19-CAR with a 4-1BB costimulatory domain.
Day −14. Apheresis collected her T cells. Lentivirus carrying the CD19-CAR transgene transduced them. The cells expanded in culture for two weeks.
Day 0. She received a low-dose lymphodepleting regimen (the optimized protocol now uses fludarabine + cyclophosphamide), then her engineered T cells were infused.
Day +3. Fever, hypotension, hypoxia. She developed severe CRS, was intubated, transferred to PICU. IL-6 levels were astronomically high. Her team, with no playbook, gave tocilizumab — an anti-IL-6 receptor antibody approved for rheumatoid arthritis — based on a hunch. Her temperature crashed within hours. She extubated days later. Tocilizumab is now standard of care for severe CRS.
Day +30. Bone marrow was deep MRD-negative — no detectable leukemia cells. CAR-T cells expanded over 1000-fold in vivo. B-cell aplasia, expected, treated with IVIG.
Today, 14+ years later. Emily remains in remission. Her CAR-T cells persisted for years as memory cells. Tisagenlecleucel — the same construct — received FDA approval in August 2017 as Kymriah. She and her family advocate for pediatric oncology research worldwide.
A 35-year arc
- 1989. Zelig Eshhar at the Weizmann Institute publishes the first "T-body" — a chimeric receptor fusing scFv to TCR ζ chain.
- 1990s-early 2000s. First-generation CARs (CD3ζ only) tested but lacked persistence — T cells died quickly.
- 2003. Carl June, Bruce Levine, David Porter (UPenn) add CD28 then 4-1BB costimulatory domains — second-generation CARs persist and proliferate.
- 2010. First adult CLL patient (Bill Ludwig) treated with CTL019 at UPenn — durable remission.
- April 2012. Emily Whitehead, first pediatric ALL treatment.
- August 2017. Tisagenlecleucel (Kymriah) FDA approval for pediatric ALL — first gene-modified cell therapy.
- October 2017. Axicabtagene ciloleucel (Yescarta) approved for DLBCL.
- 2021. Idecabtagene vicleucel (Abecma) approved for multiple myeloma (BCMA-CAR).
- 2022. Ciltacabtagene autoleucel (Carvykti) approved — cilta-cel has shown the deepest myeloma responses.
- 2024. FDA boxed warning for secondary T-cell lymphomas after CAR-T (rare); trials advancing in autoimmune disease (lupus, myasthenia, scleroderma) with striking results.
Approved CD19/BCMA CAR-T products
| Product | Target | Costim | Approved indication(s) | First FDA approval | List price (US) |
|---|---|---|---|---|---|
| Tisagenlecleucel (Kymriah) | CD19 | 4-1BB | Pediatric/young adult ALL; DLBCL; follicular lymphoma | Aug 2017 | ~$475k |
| Axicabtagene ciloleucel (Yescarta) | CD19 | CD28 | DLBCL (2nd line+); follicular lymphoma | Oct 2017 | ~$373k |
| Brexucabtagene autoleucel (Tecartus) | CD19 | CD28 | Mantle cell lymphoma; adult B-ALL | Jul 2020 | ~$373k |
| Lisocabtagene maraleucel (Breyanzi) | CD19 | 4-1BB | DLBCL; CLL/SLL; follicular lymphoma; MCL | Feb 2021 | ~$410k |
| Idecabtagene vicleucel (Abecma) | BCMA | 4-1BB | Multiple myeloma (4+ prior lines) | Mar 2021 | ~$420k |
| Ciltacabtagene autoleucel (Carvykti) | BCMA | 4-1BB | Multiple myeloma (earlier lines) | Feb 2022 | ~$465k |
Where CAR-T matters
- Pediatric/young adult B-ALL. Tisa-cel cures children who would otherwise die.
- DLBCL. Now used in second line — earlier than salvage chemo + autoSCT.
- Follicular and mantle cell lymphoma. Approved across multiple products.
- Multiple myeloma. BCMA-CARs (cilta-cel, ide-cel) — deepest responses in advanced disease.
- Autoimmune disease. 2022-2024 case series in lupus, myasthenia gravis, scleroderma show drug-free remission after a single CAR-T infusion — a paradigm shift if confirmed.
- Solid tumors. Active research in HER2, EGFR, mesothelin, GD2 — limited by antigen heterogeneity and microenvironment.
Common misconceptions
- CAR-T is a drug. It's a living, dividing, autologous cell product — closer to a transplant than a small molecule.
- One size fits all. Manufacturing is bespoke per patient. Variability in starting T cells and expansion affects outcomes.
- CRS means treatment failure. Some CRS often correlates with tumor killing — but severe CRS is life-threatening and must be treated promptly.
- Once you relapse on CD19-CAR you can re-treat. Antigen-loss escape (CD19-negative leukemia) emerges in 10-20%; need alternative targets.
- CAR-T cures everyone. Long-term remissions ~30-50% in DLBCL; most myeloma patients eventually relapse.
- Allogeneic off-the-shelf CAR-T is here. In trials, not yet matching autologous in persistence; immune rejection still a problem.
Frequently asked questions
What is the CAR construct?
A chimeric antigen receptor is a single transmembrane protein with four parts. Ectodomain: a single-chain variable fragment (scFv) — the antigen-binding portion of an antibody (heavy chain VH and light chain VL connected by a flexible linker) — that recognizes the tumor antigen directly, MHC-independent. Hinge: typically CD8α or IgG4 spacer, sets the geometry between scFv and membrane. Transmembrane: CD8α or CD28. Intracellular: a costimulatory domain (CD28 in axi-cel, 4-1BB in tisa-cel and brexu-cel) plus CD3ζ for primary T-cell receptor signaling. Second-generation CARs (one costim + CD3ζ) are the current standard; third-generation have two costimulatory domains; fourth-generation (TRUCKs) co-express cytokines.
Why is CD19 the target for B-cell lymphomas?
CD19 is a B-cell-lineage surface marker expressed on essentially all normal B cells and the vast majority of B-cell malignancies (ALL, CLL, DLBCL, follicular lymphoma, mantle cell lymphoma). It is not expressed on T cells, plasma cells (mostly), stem cells, or non-hematopoietic tissue. So a CD19-CAR kills normal B cells too — but humans can survive without circulating B cells with intravenous immunoglobulin replacement. Multiple myeloma is plasma-cell derived and CD19-negative; for myeloma the target is BCMA (idecabtagene vicleucel, ciltacabtagene autoleucel).
How are CAR-T cells manufactured?
Leukapheresis collects 5-15 × 10⁹ peripheral blood mononuclear cells from the patient. Frozen cells ship to a centralized GMP facility. T cells are isolated (typically CD4+/CD8+ selection), activated with anti-CD3/CD28 beads, transduced with a lentivirus or retrovirus encoding the CAR (clinical lentivectors integrate semi-randomly into euchromatin, ~1-3 copies per cell), and expanded for 9-14 days. Final product: 1-5 × 10⁸ CAR+ T cells, cryopreserved, shipped back. Total vein-to-vein time is typically 21-35 days. Bridging chemotherapy keeps disease controlled during manufacturing. Allogeneic (off-the-shelf) CAR-Ts from healthy donors with edited TRAC/B2M are in trials.
What is cytokine release syndrome?
Cytokine release syndrome (CRS) is the most common and characteristic CAR-T toxicity — a systemic inflammatory response from massive T-cell activation and tumor killing. Onset is typically days 1-10 after infusion, peaks around days 4-7. Symptoms: fever (always), tachycardia, hypotension, capillary leak, hypoxia, transaminitis, coagulopathy. Mediated by IL-6, IL-1, IFN-γ, TNF — often released by activated monocytes and macrophages. Grading 1-4 by ASTCT consensus. Treatment: tocilizumab (anti-IL-6R) as first-line for severe CRS; steroids if refractory; anakinra (anti-IL-1) for ICANS. Profound CRS can be fatal if untreated.
How effective is CAR-T?
Pediatric/young adult relapsed/refractory B-ALL: complete remission ~80% with tisagenlecleucel (Kymriah); ~50% remain in remission at 1 year, ~40% at 5 years — many patients who would otherwise die get long-term remissions or cures. DLBCL after ≥2 prior lines: complete remission ~40-55% with axi-cel, tisa-cel, liso-cel; durable remissions ~30-40%. Multiple myeloma after ≥4 prior lines: response rates 70-95% with cilta-cel or ide-cel, but most eventually relapse. CAR-Ts have moved earlier in lines of therapy for some indications. Solid tumors remain refractory — antigen heterogeneity, immunosuppressive microenvironment, trafficking barriers.
How much does CAR-T cost?
List prices in the US are about $400,000-$500,000 per dose. Tisagenlecleucel (Kymriah): $475,000. Axicabtagene ciloleucel (Yescarta): $373,000. Total cost including hospitalization (typically 1-3 weeks inpatient or outpatient monitoring), bridging chemo, tocilizumab, ICU care for severe CRS easily reaches $1 million. Cost-effectiveness is debated but defensible for diseases with no curative alternative. Manufacturing is the bottleneck — autologous CAR-T cannot scale linearly. Off-the-shelf allogeneic CAR-T and in vivo CAR-T (LNP-mRNA encoding CAR delivered systemically) aim to bring cost and access in line with small molecules.
What are the major risks beyond CRS?
ICANS (immune effector cell associated neurotoxicity syndrome) — confusion, aphasia, tremor, seizures, rarely cerebral edema; treated with steroids. B-cell aplasia: durable depletion of normal B cells requires IVIG replacement. Cytopenias: prolonged neutropenia, anemia, thrombocytopenia from lymphodepleting chemo and bone marrow effects. Infections: serious because of immune deficiency. Hypogammaglobulinemia. Antigen-loss escape: CD19-negative relapse occurs in 10-20% of pediatric ALL. Secondary malignancies including rare T-cell lymphomas from insertional mutagenesis (FDA boxed warning 2024). On-target off-tumor toxicity in solid-tumor CARs (e.g. HER2-CAR cardiotoxicity).